Opportunities For Increased Drug Sales To The VA

FL
Foley & Lardner
Contributor
Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
Pharmaceutical manufacturers that produce drugs in non-designated countries under the Trade Agreements Act may now have an opportunity to increase their sales to the United States government.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Pharmaceutical manufacturers that produce drugs in non-designated countries under the Trade Agreements Act (TAA) may now have an opportunity to increase their sales to the United States government. The Department of Veterans Affairs (VA) recently announced its new policy to require the listing of "all covered drugs, regardless of country of substantial transformation" on VA Schedule 65 I B, expanding coverage of drugs produced abroad.

The VA's Federal Supply Schedule (FSS) service supports the health care requirements of the VA and other federal government agencies by making over one million commercial products and services available to federal customers. The VA currently manages multiple award contracts for medical equipment, supply, pharmaceutical, and service Schedule programs. VA Schedule 65 I includes drugs, pharmaceuticals, and hematology related products.

This recent change represents a significant shift in policy. Previously, drugs manufactured in a country with which the United States does not have a trade agreement in place were excluded from Schedule 65 I contracts. The former policy required that all products offered under a VA FSS contract be U.S.-made or substantially transformed, designated country end products under the TAA, meaning that federal customers could not purchase drugs manufactured or substantially transformed in a country such as China, India, or Malaysia. Now, however, the VA can make use of a TAA exception allowing the government to purchase non-TAA-compliant products if no products that comply with the TAA are available, and a VA contracting officer can issue individual non-availability determinations for any drugs covered by Schedule 65 I B that are only available from a non-TAA country.

Although the VA's announcement provided few details about the procedures for such determinations, and deadlines for listing non-TAA-compliant covered drug products are tight, the change in policy could provide significant government sales opportunities for drug manufacturers that sell non-TAA-compliant products. More information about the Trade Agreement Act requirements and the process for current VA Schedule 65 I B contractors to add drugs and other products to their existing FSS contracts is available here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Opportunities For Increased Drug Sales To The VA

United States Food, Drugs, Healthcare, Life Sciences
Contributor
Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More